EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploration of Pyrazole‐Sulfonamide Hybrids: Synthesis, Molecular Modeling, Potential Antimicrobial, DHFR Inhibitor, and Pharmacokinetic Profile

Adhwa A Alharbi, Manal S Ebaid iD, Asmaa L Alanzy, Adel I Alalawy iD, Basma Abbas iD, Khadra B Alomari iD, Roba M S Attar iD, Nashwa M El-Metwaly iD

Chemical Biology & Drug Design · 2026

DOI: 10.1111/cbdd.70417 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2026. Verfasst von Adhwa A Alharbi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, College of Science, Taibah University, Al-Madinah Al-Munawarrah, Saudi Arabia. Hauptthemen laut MEDLINE: Sulfonamides, Pyrazoles, Tetrahydrofolate Dehydrogenase, Folic Acid Antagonists. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Umm Al-Qura University, Saudi Arabia under.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

New pyrazolyl sulfonamide conjugates 5 , 6 , and 7 were synthesized by reacting N‐(4‐(hydrazinecarbonyl) aryl) benzenesulfonamide with acetyl acetone, ethyl acetoacetate, and/or 2‐(ethoxymethylene)malononitrile. The DFT computations of the constructed derivatives exhibited comparable bent shapes. The conjugates 5a‐b and 6a‐b displayed parallel HOMO‐LUMO structures, whereas the nitro‐derivatives 5c and 6c exhibited alternative configurations of their FMOs. Furthermore, the antimicrobial activity was assessed against different bacterial and fungal pathogens. Pyrazole derivatives 5c , 6b , 7a , and 7c exhibited high activity against S. aureus (MIC = 3.125–6.25 μg/mL) and E. coli (MIC = 3.125 μg/mL), exceeding the activity of standard antibiotics, with 6b demonstrating the broadest spectrum of activity against both bacteria and fungi. The in vitro DHFR inhibitory effects of the investigated sulfonamides were examined and compared with those of methotrexate. Among the screened derivatives, hybrids 7a‐c displayed more potent inhibitory activities, thereby determining the effect of substitution patterns on activity. Additionally, the molecular docking of the manufactured analogs against the dihydrofolate reductase enzyme (PDB: 3TZF) was investigated, where hybrid 6a exhibited the highest activity with a binding score ( S = −6.5129 kcal/mol), which was greater than that of methotrexate ( S = −6.4743 kcal/mol). Moreover, pharmacokinetic characteristics were simulated using SwissADME to evaluate drug‐likeness and potential oral bioavailability. All hybrids exhibited beneficial physicochemical properties within acceptable drug‐likeness limits, confirming the pyrazole‐sulfonamide scaffold as an optimization target for future orally active drug candidates with good pharmacokinetic potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SulfonamidesPyrazolesTetrahydrofolate DehydrogenaseFolic Acid AntagonistsAnti-Infective AgentsMicrobial Sensitivity TestsMolecular Docking SimulationEscherichia coliStaphylococcus aureusStructure-Activity RelationshipAnti-Bacterial AgentsDensity Functional TheoryModels, Molecular

Stichwörter der Autor:innen

DFT calculationsDHFR inhibitionantibacterialdockingpyrazolesulfonamide

Substanzen

SulfonamidesPyrazolesTetrahydrofolate DehydrogenaseFolic Acid AntagonistsAnti-Infective AgentsAnti-Bacterial Agentspyrazole

Autor:innen und Institutionen

  • Department of Chemistry, College of Science, Taibah University, Al-Madinah Al-Munawarrah, Saudi Arabia.
  • Department of Chemistry, College of Science, Northern Border University, Arar, Saudi Arabia.
  • Department of Chemistry of Natural Compounds, Pharmaceutical and Drug Industries Research Institute, National Research Center, Cairo, Egypt.
  • Department of Chemistry, College of Science, Qassim University, Buraidah, Saudi Arabia.
  • Department of Biochemistry, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia.
  • Department of Biological Sciences, College of Science, University of Jeddah, Jeddah, Saudi Arabia.

ORCID-Profile: Manal S Ebaid, Adel I Alalawy, Basma Abbas, Khadra B Alomari, Roba M S Attar, Nashwa M El-Metwaly

Förderung

  • Umm Al-Qura University, Saudi Arabia under

Zitieren

APA

Alharbi, A. A., Ebaid, M. S., Alanzy, A. L., Alalawy, A. I., Abbas, B., Alomari, K. B., Attar, R. M. S., & El-Metwaly, N. M. (2026). Exploration of Pyrazole‐Sulfonamide Hybrids: Synthesis, Molecular Modeling, Potential Antimicrobial, DHFR Inhibitor, and Pharmacokinetic Profile. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70417

Vancouver

Alharbi AA, Ebaid MS, Alanzy AL, Alalawy AI, Abbas B, Alomari KB, et al. Exploration of Pyrazole‐Sulfonamide Hybrids: Synthesis, Molecular Modeling, Potential Antimicrobial, DHFR Inhibitor, and Pharmacokinetic Profile. Chemical Biology & Drug Design. 2026. doi:10.1111/cbdd.70417

BibTeX
@article{Alharbi2026,
  author = {Alharbi, Adhwa A and Ebaid, Manal S and Alanzy, Asmaa L and Alalawy, Adel I and Abbas, Basma and Alomari, Khadra B and Attar, Roba M S and El-Metwaly, Nashwa M},
  title = {Exploration of Pyrazole‐Sulfonamide Hybrids: Synthesis, Molecular Modeling, Potential Antimicrobial, DHFR Inhibitor, and Pharmacokinetic Profile},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  doi = {10.1111/cbdd.70417}
}
Kostenlos starten →